![]() |
6th ESACP Congress, Heidelberg, April 7-11, 1999 |
A072
Presently it is still difficult to determine for an individual patient, with
advanced Lung Cancer (LC), which treatment is the most appropriate and to
what extent the patient will benefit from it. 93 patients with LC were
prospectively studied to evaluate if FCM-DNA Ploidy and S-Phase Fraction
(SPF), associated to known clinical and laboratory data, could serve as
predictors of the disease response to therapy. FCM data were measured
following recent consensus guidelines to analyse fresh frozen samples
obtained either by bronchial biopsies or brushings or transthoracic fine
needle aspiration. The survival multivariate analysis identified the:
performance status (Zubrod) (p=0.000), stage (p=0.001), leukocyte (p=0.000)
and lymphocyte (p=0.000) counts, alkaline phosphatase (p=0.039), DNA ploidy
(p=0.046) and the SPF (p=0.000) as independent prognostic factors. DNA
aneuploidy and a SPF * 15%, were associated with a better prognosis, contrary
to that which is referred to in the majority of the literature. The progression
analysis identified the performance status (p=0.001), SPF (p=0.011) and total
serum proteins (p=0.036), as significant predictors. With these 3 parameters
a logistic model was constructed which, when applied to the study population,
identified more than 83% of patients whose disease progressed and 82.5% of
those who at least stabilised. These results point out the utility of some
clinical parameters and DNA ploidy and SPF as prognostic factors and as
indicators of disease response to therapy.
FCM-DNA PLOIDY AND S-PHASE FRACTION ARE USEFULL INDICATORS OF LUNG CANCER
RESPONSE TO THERAPIY
Hespanhol V 1, Sansonetty F 2, Amendoeira I 3, Marques A 1
1) Servicio de Pneumologia, Hospital de S. Joao, Porto,
2) Laboratorio de Citometria, IPATIMUP, Porto,
3) Servicio de Anatomia Patologica, Hospital de S.Joao, Porto, Portugal